A Single-centre, Single Dose, Randomized, Open-label, Three Period, Six Sequence, Cross Controlled Study to Assess the Relative Bioavailability of the New and Traditional Formulations on SHR6390 in Healthy Subjects
Latest Information Update: 14 Oct 2021
At a glance
- Drugs Dalpiciclib (Primary)
- Indications Breast cancer; Head and neck cancer; Malignant melanoma; Solid tumours
- Focus Pharmacokinetics
- Sponsors Jiangsu Hengrui Medicine Co.
- 11 Oct 2021 Status changed from not yet recruiting to completed.
- 17 Dec 2020 New trial record